Last reviewed 2026-04-23 · How we verify

AIR-001 SAD dose level 1

AIRNA Corporation · Phase 1 active Small molecule

AIR-001 SAD dose level 1 is a Small molecule drug developed by AIRNA Corporation. It is currently in Phase 1 development.

At a glance

Generic name	AIR-001 SAD dose level 1
Sponsor	AIRNA Corporation
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AIR-001 SAD dose level 1 CI brief — competitive landscape report
AIR-001 SAD dose level 1 updates RSS · CI watch RSS
AIRNA Corporation portfolio CI

Frequently asked questions about AIR-001 SAD dose level 1

What is AIR-001 SAD dose level 1?

AIR-001 SAD dose level 1 is a Small molecule drug developed by AIRNA Corporation.

Who makes AIR-001 SAD dose level 1?

AIR-001 SAD dose level 1 is developed by AIRNA Corporation (see full AIRNA Corporation pipeline at /company/airna-corporation).

What development phase is AIR-001 SAD dose level 1 in?

AIR-001 SAD dose level 1 is in Phase 1.

Manufacturer: AIRNA Corporation — full pipeline
Compare: AIR-001 SAD dose level 1 vs similar drugs
Pricing: AIR-001 SAD dose level 1 cost, discount & access